Ventyx Biosciences
San Diego
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $468.6M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2024)
- Ticker: nasdaq:VTYX
- Website: ventyxbio.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ventyx-biosciences-14039 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.